IMNM
NASDAQ
$22.16
Immunome Inc (IMNM)
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapies for oncology and infectious diseases. The company is headquartered in Exton, Pennsylvania.
Sector:
Healthcare
Industry:
Biotechnology
Strong Buy
Target: $35.77 (+61.42%)
Market Cap
$2.59B
FCF 5Y CAGR
+70.73%
Free Cash Flow Yield
-7.92%
Beta (5Y)
1.64
Price Chart
Valuation
Market Cap$2.59B
P/S646.50
P/B4.35
Profitability
Total Revenue (TTM)$4.01M
Gross Profit (TTM)-$183M
EBITDA-$236M
Operating Margin-5699%
EPS-$2.22
Financial Health
Free Cash Flow Yield-7.92%
Growth & Risk
FCF 5Y CAGR+70.73%
Beta (5Y)1.64
Sharpe Ratio1.38